Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

298P - Managing locally advanced cervical cancer: Insights from a tertiary care center and a 3-year follow-up on outcomes

Date

02 Dec 2023

Session

Poster Display

Presenters

Ambedkar Yadala

Citation

Annals of Oncology (2023) 34 (suppl_4): S1584-S1598. 10.1016/annonc/annonc1383

Authors

A. Yadala1, B.S. Gundapuneedi2, L. Ramachandran3, J. Pandjatcharam4

Author affiliations

  • 1 Radiation Oncology Dept, Building 7, Regional Cancer Centre, JIPMER, 605006 - Puducherry/IN
  • 2 Radiation Oncology, JIPMER - Jawaharlal Institute of Postgraduate Medical Education and Research, 605006 - Puducherry/IN
  • 3 Radiation Oncology Dept., JIPMER - Jawaharlal Institute of Postgraduate Medical Education and Research, 605006 - Puducherry/IN
  • 4 Radiation Oncology Department, JIPMER - Jawaharlal Institute of Postgraduate Medical Education and Research, 605006 - Puducherry/IN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 298P

Background

Cervical Cancer is one of the leading causes of cancer mortality in Indian women.Most of the women present in advanced stages of cervical cancer. Although CTRT remains the standard of care there were several challenges in implementation. In this study we assesed 3-year outcomes of LACC patients and the factors impacted the outcome.

Methods

We retrospectively analysed the records and follow up data of 131 patients of locally advanced cervical cancer registered in 2019. We noted the baseline characteristics include demographic data, comorbidities, histology and stage, treatment details, follow up data which include their disease status, death. Table: 298P

Baseline characterstics

Variables N=131 (%)
Comorbidities
Diabetes Mellitus 19 14.5
Hypertension 18 13.7
Others 16 12.2
None 78 59.5
ECOG
1 98 74.8
2 29 22.1
3 4 3.1
Histology
Squamous Cell Carcinoma 121 92.4
Adenocarcinoma 6 4.6
Others 4 3.1
Stage (FIGO 2018)
IB 8 6.1
IIA 5 3.8
IIB 47 35.9
IIIA 6 4.6
IIIB 47 35.9
IIIC1 9 6.9
IIIC2 3 2.3
IVA 6 4.6

Results

The median follow-up time was 45.5 months (IQR - 39.7-47.4). 5 patients had defaulted radiotherapy, 5 defaulted brachytherapy and 9 deferred brachytherapy. The average time from diagnosis to start of treatment is 109 days. 3-year OS was 78.6%. Stage-wise survival was IB (100%), IIA (100%), IIB (78.7%), IIIA (83.3%), IIIB (78.7%), IIIC (66.6%) & IVA (50%). 82.4% in CTRT patients and 72.4% in RT alone were alive. Dose >85Gy resulted in better local control and survival. The 3-year OS of patients with Overall Treatment Time <56 days is 89.1% while OTT >56 days is 80.7% (p=0.215).

Conclusions

The findings of this study highlighted the importance of concurrent chemoradiation in locally advanced cervical cancer. Doses >85 Gy to the disease and OTT <56 days showed better outcomes. Strategies to improve compliance to CTRT and image-guided adaptive brachytherapy will help in improved local control and survival. In low-middle income countries, these outcomes are also impacted by non-compliance and long wait-list to treatment, which is often due to logistical and socio-cultural barriers.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.